-
公开(公告)号:US10438688B2
公开(公告)日:2019-10-08
申请号:US16113718
申请日:2018-08-27
Applicant: Purdue Research Foundation
Abstract: An in silico screening method generated compounds that are against laminin receptor 37LR and their anti-cancer functions in prostate cancer cell lines are disclosed herein. A group of derivatives based on the hit compound from the in silico screening are synthesized and tested with improved IC50 value that can have relevant clinical use for prostate cancer or osteoarthritis.
-
公开(公告)号:US11022604B2
公开(公告)日:2021-06-01
申请号:US16555486
申请日:2019-08-29
Applicant: Purdue Research Foundation
IPC: G01N33/50 , G01N33/574 , G16B15/30 , G16C20/60 , G16C20/50 , A61K31/497
Abstract: An in silico screening method generated compounds that are against laminin receptor 37LR and their anti-cancer functions in prostate cancer cell lines are disclosed herein. A group of derivatives based on the hit compound from the in silico screening are synthesized and tested with improved IC50 value that can have relevant clinical use for prostate cancer or osteoarthritis.
-
公开(公告)号:US20200064334A1
公开(公告)日:2020-02-27
申请号:US16555486
申请日:2019-08-29
Applicant: Purdue Research Foundation
IPC: G01N33/50 , G01N33/574 , A61K31/497 , G16C20/60 , G16C20/50 , G16B15/30
Abstract: An in silico screening method generated compounds that are against laminin receptor 37LR and their anti-cancer functions in prostate cancer cell lines are disclosed herein. A group of derivatives based on the hit compound from the in silico screening are synthesized and tested with improved IC50 value that can have relevant clinical use for prostate cancer or osteoarthritis.
-
公开(公告)号:US20190065669A1
公开(公告)日:2019-02-28
申请号:US16113718
申请日:2018-08-27
Applicant: Purdue Research Foundation
IPC: G06F19/16 , C40B30/02 , A61K31/497 , A61P35/00 , A61P19/02
CPC classification number: G16B15/00 , A61K31/497 , A61P19/02 , A61P35/00 , G16B15/30 , G16B35/00 , G16C20/50 , G16C20/60 , G16C20/64
Abstract: An in silico screening method generated compounds that are against laminin receptor 37 LR and their anti-cancer functions in prostate cancer cell lines are disclosed herein. A group of derivatives based on the hit compound from the in silico screening are synthesized and tested with improved IC50 value that can have relevant clinical use for prostate cancer or osteoarthritis.
-
-
-